This is one company with a good chance at takeover by a larger entity in Europe or USA.
The right size for easy takeover as well as easy regulatory approval.
Even if the executives don't like the idea, investors can override them.
I've been following trade alerts from the Penny Stock 101 org newsletter, and I've been consistanly beating the market. If you want to get an early jump on the fastest moving NASDAQ, NYES and OTC stocks signup now.Just on an email stating they have a new pick coming tomorrow!
After the shenanigans the company pulled implying there was a merger in the offing just before the prior CEO's retirement, how can anything the company puts out be taken seriously?
Talked to my friend who works at N.J. territory and he say business in their region has been very slow. Company laid off skilled technicians and pile up work load on existing employees to make them work from 7 to 8 including weekend without any work pay. Not a good sign.
As of first week of Aug. 2015 contract price is $74 minus 15% comes about $62.90 as the insider employees cost. St. Jude has the option of buying at today's market price to take care of their employees which is about $61 to $61.50. I say St. Jude stock will recover back over $63 to $64 easily before Xmas holiday. Stock price today is about their 52 weeks low so I would not be surprised for it to recover a few dollars at the least.
I expect STJ to trade back over $63.50 before Xmas as a guarantee. Cheers.
Sentiment: Strong Buy
The price per share on ssh is low right now before fda approval is granted. Ssh is a real good money maker.
Sentiment: Strong Buy
STJ has the near perfect takeover profile.
1. Industry group, medical, takeovers prolific.
2. Aging population.
3. Superior balance sheet.
4. Smaller of the highest quality in the group.
5. Due for a takeover in this niche of cardiology.
Great organization, BUT, they pester their donors with at a minimum 2 letters or calls a week to ask for more! They've also sold my info to other charities which I told them not to. Sadly I've dropped out & have told them so!!
Moody's has looked at LVAD's growth and impact on bottom line? :)
any investigation would center on FT, their the ones that posted the rumor.All CNBC did was discuss it, they didn't start it.